Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Sanofi-Aventis pushes harder for Genzyme with $18.5B acquisition bid

August 30, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Pharmaceutical giant Sanofi-Aventis made public a letter it sent over the weekend to Genzyme Corp. CEO Henri Termeer, publicly confirming its previously reported bid for Genzyme Corp. (Nasdaq: GENZ) and moved to prod Genzyme shareholders into embracing a deal that management of the...

Bend Research Receives Patent for Preparing Spray-Dried Drug Dispersions Using Pressure Nozzles

August 30, 2010 5:35 am | by Bio-Medicine.Org | News | Comments

BEND, Ore., Aug. 30 /- Bend Research Inc. ( www.bendres.com ), a leading independent drug-formulation development and manufacturing company, announced today that it has received a new U.S. patent covering a process for making spray-dried solid amorphous dispersions of drugs using pressure...

TOPICS:

Millennium Laboratories Announces New Chief Operating Officer David Cohen

August 30, 2010 5:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Aug. 30 /- Millennium Laboratories , a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today the appointment of David Cohen to Chief Operating Officer. In his capacity as COO, Mr. Cohen is responsible for...

TOPICS:
Advertisement

Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010

August 30, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Aug. 30 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: Data from mipomersen Phase 3 trial in heFH patients presented at ESCWhen: Wednesday, September 1, 2010 at 4:00 p.m. ET / 1:00 p.m. PTWhere: www.isispharm.comHow: Live on the...

TOPICS:

Circadian rhythms: Their role and dysfunction in affective disorder

August 30, 2010 5:33 am | by EurekAlert | News | Comments

(European College of Neuropsychopharmacology) Biological clocks play a major role in affective disorders. Synchronizing impaired circadian rhythms, improving sleep, or paradoxically staying awake most of the night can be extremely helpful to treat patients with depression and bipolar...

TOPICS:

3M to acquire Cogent for about $933 million

August 30, 2010 4:45 am | by The Associated Press | News | Comments

Technology company 3M Co. says it has agreed to acquire Cogent Inc. in a deal worth about $933 million.Cogent, based in Pasadena, Calif., develops automated systems that read finger and palm prints.Cogent's board of directors has agreed to the deal, announced Monday, and is recommending that...

MedCath sells South Dakota hospital for $20M

August 30, 2010 4:45 am | by The Associated Press | News | Comments

MedCath will sell its stake in Avera Heart Hospital of South Dakota to Avera McKennan for $20 million, the healthcare provider said Monday.MedCath owns one-third of the hospital and management rights.After the sale, Avera McKennan will own two-thirds of Avera Heart. Avera McKennan is a member...

SQI Diagnostics says higher research costs increased third-quarter loss

August 30, 2010 3:45 am | by The Associated Press | News | Comments

SQI Diagnostics Inc. (TSXV:SQD) has reported a loss of $1.6 million for the third quarter as increased expenses weighed on its quarterly results.The Toronto-based medical systems company said Monday its losses were equal to five cents a share, for the three months ended June 30. That compared...

Advertisement

Covidien Completes Sale of Specialty Chemicals Business

August 30, 2010 3:33 am | by Covidien | News | Comments

DUBLIN, Aug 30, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced sale of its Specialty Chemicals business to an affiliate of New Mountain Capital, L.L.C. for a cash purchase price...

TOPICS:

Covidien Completes Sale of Sleep Therapy Product Line

August 30, 2010 3:32 am | by Covidien | News | Comments

DUBLIN, Aug 30, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced sale of its Sleep Therapy continuous positive airway pressure (CPAP) and Bi-level products to PH Invest, a...

TOPICS:

Why Betting on 3D?

August 30, 2010 2:32 am | by I-Micronews | News | Comments

The continuation of Moore?s Law appears less in doubt than ever. Companies such as Intel, ST, AMD (via GlobalFoundries) and IBM are testing FinFETS and ETSOI and work is being done on the back end to ensure that these new structures can be manufactured with sufficient yield, according to...

New genomic marker for tuberculosis may help identify patients who will develop the disease

August 29, 2010 10:31 pm | by EurekAlert | News | Comments

(Nationwide Children's Hospital) It may soon be possible to identify patients who will develop tuberculosis, as scientists have identified changes in the blood specific to the disease. These findings are from an international study published in the Aug. 19 issue of Nature and conducted by...

TOPICS:

New Court Ruling Could Cripple Stem-Cell Research

August 29, 2010 8:31 pm | by Massachusetts Institute of Technology | News | Comments

Once again, federal funding restrictions cast uncertainty over the field.

TOPICS:

Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme

August 29, 2010 1:31 pm | by Bio-Medicine.Org | News | Comments

PARIS, Aug. 29 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that it has submitted a non-binding proposal to acquire Genzyme (Nasdaq: GENZ ) in an all-cash transaction valued at approximately $18.5 billion. Under the terms of the proposed acquisition, Genzyme...

TOPICS:

McMaster study contradicts reports of problems with blood-thinner

August 29, 2010 7:32 am | by EurekAlert | News | Comments

(McMaster University) New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading